Edwards Kathryn M, Sabow Adam, Pasternak Andrew, Boslego John W
Vanderbilt Vaccine Research Program, Vanderbilt University School of Medicine, 1161 21st Avenue South, CCC-5323 Medical Center North, Nashville, TN 37232, USA.
Curr Top Microbiol Immunol. 2009;333:471-93. doi: 10.1007/978-3-540-92165-3_23.
The global need for a pandemic influenza vaccine is large. High-income countries have stated their intent to provide universal access for pandemic influenza vaccine to their populations. Assuming that a two-dose schedule would be needed, providing universal coverage globally would represent approximately 6.5 billion two-dose courses or 13 billion doses. In the best case scenario, should an outbreak of pandemic influenza occur in the near term, using H5N1 as a proxy for the pandemic virus, the total available doses for the global population within six months of an out break would be only 1.2 billion courses or 2.4 billion doses. In addition, current stockpiles of pandemic influenza vaccine are limited. However, promising developments are occurring with respect to global capacity, technological innovation, and global conviction that offer potential solutions to the problem of pandemic influenza vaccine supply for the world's population.
全球对大流行性流感疫苗的需求巨大。高收入国家已表示打算为其民众提供普遍接种大流行性流感疫苗的机会。假设需要接种两剂疫苗,那么在全球范围内实现普遍覆盖将意味着约65亿剂两剂次的接种量,即130亿剂。在最佳情况下,如果近期发生大流行性流感疫情,以H5N1作为大流行病毒的代表,疫情爆发后六个月内全球人口可获得的疫苗总量仅为12亿剂次,即24亿剂。此外,目前大流行性流感疫苗的库存有限。然而,在全球产能、技术创新以及全球共识方面正出现一些有前景的进展,这些进展为解决全球人口的大流行性流感疫苗供应问题提供了潜在的解决方案。